Literature DB >> 19185906

Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease.

Nauder Faraday1, Lisa R Yanek, Dhananjay Vaidya, Brian Kral, Rehan Qayyum, J Enrique Herrera-Galeano, Taryn F Moy, Diane M Becker, Lewis C Becker.   

Abstract

BACKGROUND: Markers of systemic inflammation, including blood leukocyte count, are associated with increased cardiovascular risk, but the mechanisms underlying this association are unclear. Leukocytes may promote platelet reactivity and thrombus formation, providing a basis for increased risk, but a relation between leukocyte count and platelet function has not been studied.
METHODS: We evaluated the relation of blood leukocyte count, C-reactive protein (CRP), and interleukin-6 (IL-6) to platelet aggregation to collagen, ADP and arachidonic acid, and to urinary excretion of 11-dehydro thromboxane B2. Studies were conducted in 1600 individuals (45.0+/-12.9 years, 42.7% male) at risk for coronary artery disease (CAD) before and after low dose aspirin.
RESULTS: At baseline, platelet reactivity increased with increasing quartile of leukocyte count (median counts for each quartile were normal) for all measures of platelet function (P<0.0001). These relations were unchanged by aspirin. The relation between leukocyte count and each measure of platelet reactivity remained significant (P<0.05) after multivariable adjustment for CRP, IL-6, cardiac risk factors, hematologic variables, and platelet thromboxane production. CRP and IL-6 were independently associated with few measures of platelet reactivity.
CONCLUSIONS: Increasing quartile of leukocyte count, even within the normal range, is associated with increasing platelet reactivity in individuals at risk for CAD. This relationship is not altered by aspirin and is independent of inflammatory markers and platelet thromboxane production. Additional studies are needed to determine the mechanism(s) for this association and therapies to reduce cardiovascular risk in patients with elevated leukocyte counts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185906      PMCID: PMC2763116          DOI: 10.1016/j.thromres.2008.12.031

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  42 in total

Review 1.  Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance.

Authors:  Scott A McKee; David C Sane; Efthymios N Deliargyris
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

Review 2.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

3.  Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction.

Authors:  Robert Dragu; Shafik Huri; Robert Zukermann; Mahmoud Suleiman; Diab Mutlak; Yoram Agmon; Michael Kapeliovich; Rafael Beyar; Walter Markiewicz; Haim Hammerman; Doron Aronson
Journal:  Atherosclerosis       Date:  2006-12-14       Impact factor: 5.162

4.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.

Authors:  E Lindmark; E Diderholm; L Wallentin; A Siegbahn
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

5.  The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes.

Authors:  Michael N Zairis; Evdokia N Adamopoulou; Stavros J Manousakis; Anastassios G Lyras; George P Bibis; Olga S Ampartzidou; Charalambos S Apostolatos; Filippos A Anastassiadis; John J Hatzisavvas; Spyros K Argyrakis; Stefanos G Foussas
Journal:  Atherosclerosis       Date:  2006-09-08       Impact factor: 5.162

6.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

7.  Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.

Authors:  John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

8.  Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection.

Authors:  A Modica; F Karlsson; T Mooe
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

9.  Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease.

Authors:  Georg Endler; Alexandra Klimesch; Heike Sunder-Plassmann; Martin Schillinger; Markus Exner; Christine Mannhalter; Nelli Jordanova; Günter Christ; Renate Thalhammer; Kurt Huber; Raute Sunder-Plassmann
Journal:  Br J Haematol       Date:  2002-05       Impact factor: 6.998

10.  Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.

Authors:  Nauder Faraday; Lisa R Yanek; Rasika Mathias; J Enrique Herrera-Galeano; Dhananjay Vaidya; Taryn F Moy; M Daniele Fallin; Alexander F Wilson; Paul F Bray; Lewis C Becker; Diane M Becker
Journal:  Circulation       Date:  2007-04-30       Impact factor: 29.690

View more
  6 in total

1.  Greater collagen-induced platelet aggregation following cyclooxygenase 1 inhibition predicts incident acute coronary syndromes.

Authors:  Rehan Qayyum; Diane M Becker; Lisa R Yanek; Nauder Faraday; Dhananjay Vaidya; Rasika Mathias; Brian G Kral; Lewis C Becker
Journal:  Clin Transl Sci       Date:  2014-07-25       Impact factor: 4.689

2.  Whole exome sequencing in the Framingham Heart Study identifies rare variation in HYAL2 that influences platelet aggregation.

Authors:  John D Eicher; Ming-Huei Chen; Achilleas N Pitsillides; Honghuang Lin; Narayanan Veeraraghavan; Jennifer A Brody; Ginger A Metcalf; Donna M Muzny; Richard A Gibbs; Diane M Becker; Lewis C Becker; Nauder Faraday; Rasika A Mathias; Lisa R Yanek; Eric Boerwinkle; L Adrienne Cupples; Andrew D Johnson
Journal:  Thromb Haemost       Date:  2017-03-16       Impact factor: 5.249

3.  Genome-wide association study of platelet aggregation in African Americans.

Authors:  Rehan Qayyum; Lewis C Becker; Diane M Becker; Nauder Faraday; Lisa R Yanek; Suzanne M Leal; Chad Shaw; Rasika Mathias; Bhoom Suktitipat; Paul F Bray
Journal:  BMC Genet       Date:  2015-05-30       Impact factor: 2.797

4.  Integrity of Induced Pluripotent Stem Cell (iPSC) Derived Megakaryocytes as Assessed by Genetic and Transcriptomic Analysis.

Authors:  Kai Kammers; Margaret A Taub; Ingo Ruczinski; Joshua Martin; Lisa R Yanek; Alyssa Frazee; Yongxing Gao; Dixie Hoyle; Nauder Faraday; Diane M Becker; Linzhao Cheng; Zack Z Wang; Jeff T Leek; Lewis C Becker; Rasika A Mathias
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

5.  White blood cell count and clustered components of metabolic syndrome: A study in western Iran.

Authors:  Mohammad-Taghi Hedayati; Mahdi Montazeri; Negin Rashidi; Elham Yousefi-Abdolmaleki; Mohammad-Ali Shafiee; Ali Maleki; Maryam Farmani; Mohammad Montazeri
Journal:  Caspian J Intern Med       Date:  2021

6.  Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients.

Authors:  Mariana Muñoz-Esquerre; José Luis Ferreiro; Daniel Huertas; Ana Lucrecia Marcano; Marta López-Sánchez; Gerard Roura; Joan Antoni Gómez-Hospital; Jordi Dorca; Angel Cequier; Salud Santos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.